Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Matthias Magoola
Computational design and translational development of TCR-mimic scFv antibodies for peptide-HLA neoantigen targeting
Abstract Single-chain variable fragments (scFvs) penetrate tissue more effectively than full antibodies and are simpler to produce, but the mutant proteins that define a tumor are predominantly intracellular and therefore inaccessible to conventional antibodies. What is accessible is the mutation-derived peptide displayed on cell-surface HLA. This review concerns TCR-mimic scFvs directed at those peptide-HLA complexes.
Engineering Universal Cancer Immunity: Non-Tumor-Specific mRNA Vaccines Trigger Epitope Spreading in Cold Tumors
This version is not peer-reviewed. Matthias Magoola,Sarfaraz K. Niazi * Matthias Magoola,Sarfaraz K. Niazi * This version is not peer-reviewed. The landscape of cancer immunotherapy must shift from personalized neoantigen vac-cines toward universal platforms that leverage innate immune activation.
Debunking alternative fuel hoaxes
No Excerpt By Dr. Matthias Magoola Self-styled Zimbabwean inventor Maxwell Chikumbutso is making headlines again after being hosted by President Emmerson Mnangagwa at State House, Harare on January 28, by claiming he had developed a vehicle powered by radio frequency (RF) waves.
MicroRNA Nobel Prize: Timely Recognition and High Anticipation of Future Products-A Prospective Analysis
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery-A Humanitarian Cause
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Innovative Therapeutic Strategies in Alzheimer’s Disease: A Synergistic Approach to Neurodegenerative Disorders
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Unlocking the Future of Drug Development: Generative AI, Digital Twins, and Beyond
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Transcytosis-Driven Treatment of Neurodegenerative Disorders by mRNA-Expressed Antibody-Transferrin Conjugates
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Optimizing Lead Compounds: The Role of Artificial Intelligence in Drug Discovery
Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 1 April 2024 / Approved: 1 April 2024 / Online: 1 April 2024 (13:35:22 CEST) Niazi, S.K.; Mariam, Z.; Magoola, M. Optimizing Lead Compounds: The Role of Artificial Intelligence in Drug Discovery. Preprints 2024, 2024040055. https://doi.org/10.20944/preprints202404.0055.v1 Niazi, S.K.; Mariam, Z.; Magoola, M. Optimizing Lead Compounds: The Role of Artificial Intelligence in Drug Discovery. Preprints 2024, 2024040055.
Universal mRNA-based HIV Vaccine for Acute and Latent Infections
Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 15 March 2024 / Approved: 18 March 2024 / Online: 18 March 2024 (11:24:43 CET) Niazi, S.K.; Magoola, M. Universal mRNA-based HIV Vaccine for Acute and Latent Infections. Preprints 2024, 2024031035. https://doi.org/10.20944/preprints202403.1035.v1 Niazi, S.K.; Magoola, M. Universal mRNA-based HIV Vaccine for Acute and Latent Infections. Preprints 2024, 2024031035.
Unlocking the Future of Drug Development: Generative AI, Digital Twins, and Beyond
Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 15 March 2024 / Approved: 15 March 2024 / Online: 15 March 2024 (19:11:07 CET) Mariam, Z.; Niazi, S.K.; Magoola, M. Unlocking the Future of Drug Development: Generative AI, Digital Twins, and Beyond. Preprints 2024, 2024030919. https://doi.org/10.20944/preprints202403.0919.v1 Mariam, Z.; Niazi, S.K.; Magoola, M. Unlocking the Future of Drug Development: Generative AI, Digital Twins, and Beyond.
mRNA-Delivered Transcytosis Enabled Treatment of Neurodegenerative Diseases
Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 13 March 2024 / Approved: 13 March 2024 / Online: 14 March 2024 (08:12:17 CET) Niazi, S.K.; Magoola, M. mRNA-Delivered Transcytosis Enabled Treatment of Neurodegenerative Diseases. Preprints 2024, 2024030802. https://doi.org/10.20944/preprints202403.0802.v1 Niazi, S.K.; Magoola, M. mRNA-Delivered Transcytosis Enabled Treatment of Neurodegenerative Diseases. Preprints 2024, 2024030802.
Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease
Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 29 February 2024 / Approved: 29 February 2024 / Online: 29 February 2024 (12:55:04 CET) Niazi, S.K.; Magoola, M.; Mariam, Z. Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease. Preprints 2024, 2024021734. https://doi.org/10.20944/preprints202402.1734.v1 Niazi, S.K.; Magoola, M.; Mariam, Z.
Advances in Escherichia coli-Based Therapeutic Protein Expression: Mammalian Conversion, Continuous Manufacturing, and Cell-Free Production
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
mRNA and Synthesis-Based Therapeutic Proteins: A Non-Recombinant Affordable Option
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Matthias
Contact Matthias, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack